首页> 外文期刊>QJM: Monthly journal of the Association of Physicians >Co-occurrence of second primary malignancy in patients with thyroid cancer
【24h】

Co-occurrence of second primary malignancy in patients with thyroid cancer

机译:Co-occurrence of second primary malignancy in patients with thyroid cancer

获取原文
获取原文并翻译 | 示例
       

摘要

Background: The discovery of asynchronous or synchronous double or multiple malignancies in patients is not uncommon. The co-occurrence of second primary malignancy (SPM) could be randomly occurring or association with risk factors such as environmental, genetic predisposition and therapy-related.Materials and methods: We retrieved ~ 782 million claim records consisting of 10.8 million males and 10.6 million females from Taiwan's National Health Insurance, which were collected for a period of 3 years (January 2000-December 2002). All the patient records were stratified by gender and ages at a 20-year interval with SPMs and specific groups. Interestingness or Q-value was used to measure strength of the disease-disease associations. Results: A total of 9423 thyroid cancer (female: 7483, male: 1940), 276 184 SPM (female: 141 023, male: 135 161) and 861 co-occurrence cases (female: 583, male: 278) were recorded. The co-occurrence incidence rate of head and neck, breast, digestive system and lung was 1.93, 1.59, 1.44 and 1.18, respectively. Malignancy of salivary glands, laryngx, sarcoma, lymphoid tissue, mouth, central nervous system and lungs found Q-value >10. Malignancies with intermediate Q-values (5.0-9.9) were observed in nasopharynx, kidney and ureter, breast, stomach and skin. Prostate, leukemia, urinary bladder, ovary, colon, liver and uterine cervix cancer have lower Q-values (1.0-4.9).Conclusion: Co-occurrence ratio of thyroid cancer and SPM was high, occurred in all organ systems. We postulated that the aggressive use of modern diagnostic modalities, aggressive radioiodine treatment, pre-existing molecular oncogen mutations, and thyroid hormone for simultaneously supple-mentary and suppressive therapies were responsible.

著录项

  • 来源
  • 作者单位

    Department of Nuclear Medicine, Taipei Medical University Hospital, Taipei, Taiwan, Division of;

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Medical;

    School of Health Care Administration, Taipei Medical University Hospital, Taipei, TaiwanGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 医药、卫生;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号